ETF profile for Tema Oncology ETF (CANC) from the issuer: top holdings, net assets, expense ratio and shares outstanding.
CANC ETF Profile
| Family: |
Tema |
| Name: |
Tema Oncology ETF |
|
|
| Inception Date: |
15-Aug-2023 |
| Termination Date: |
|
| Investment Objective: |
The actively managed Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations. Example companies include large pharmaceutical firms, diagnostic focused businesses with products used to diagnose cancer (such as liquid biopsies or cancer genomic screening), medical device companies focused on cancer treatment, and healthcare service providers with a specific strategic focus on helping treat and manage cancer. |
|
|
| Prospectus |
|
|
|
| Top 10 Holdings |
|
|
| Revolution Medicines Inc |
RVMD |
5.1900% |
| Merck & Co Inc |
MRK |
5.0300% |
| Eli Lilly & Co |
LLY |
4.9800% |
| Cogent Biosciences Inc |
COGT |
4.6600% |
| Genmab A/S |
GMAB |
4.6300% |
| Novartis AG |
NOVN |
4.0400% |
| BeOne Medicines Ltd |
ONC |
3.8600% |
| Halozyme Therapeutics Inc |
HALO |
3.8500% |
| AbbVie Inc |
ABBV |
3.7100% |
| Exelixis Inc |
EXEL |
3.5300% |
|
Top 10 Holdings Weight: |
43.5% |
| Number of Holdings: |
58 |
| Shares Outstanding: |
5,110,000 |
| Total Net Assets: |
209,442,032 |
| NAV: |
40.97 |
| Net Expense Ratio: |
0.75% |
|
|
| Asset Class: |
Equities (Stocks) |
| Developed or Emerging: |
Developed Market Funds |
| Country: |
|
| Region: |
|
| Strategy: |
|
| Currency: |
|
| Commodity: |
|
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Dividend Type: |
|
| Tax Exempt State: |
|
| Maturity Duration: |
|
| Market Cap: |
Broad Market / Multi-Cap |
| Credit Quality: |
|
| Mortgage Bond Types: |
|
| Bond Type: |
|
| Gov't Bond Types: |
|
| Reit Type: |
|
| Leverage Direction/Factor: |
|
| Is Currency Hedged: |
No |
| US or Ex-US: |
Global |
